Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation (Tables)

Share-based compensation (Tables)

9 Months Ended

Sep. 30, 2019

Summary of share-based compensation expense included in the unaudited consolidated statements of operations

The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):


		Three months ended			Nine months ended
		September 30,			September 30,
	2019		2018		2019		2018
Research and development	$	144	$	2,053	$	2,951	$	6,338
General and administrative		1,676		1,989		5,544		6,115
	$	1,820	$	4,042	$	8,495	$	12,453

Summary of share options and options which have a nominal exercise price

The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:


		Three months ended			Nine months ended
		September 30,			September 30,
	2019		2018		2019		2018
Number of options over ordinary shares granted		3,733,359		757,273		15,477,255		12,187,614
Weighted average fair value of ordinary shares options	$	0.31	$	1.09	$	0.48	$	0.82
Number of additional options with a nominal exercise price granted		743,292		1,259,760		7,700,658		7,966,716
Weighted average fair value of options with a nominal exercise price	$	0.51	$	1.67	$	0.89	$	1.40